Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aldoxorubicin - ImmunityBio

Drug Profile

Aldoxorubicin - ImmunityBio

Alternative Names: Aldoxorubicin hydrochloride; DOXO-EMCH; Doxorubicin-6-maleimidocaproyl hydrazone; INNO-206; Tumour-targeted doxorubicin conjugate - LadRx Corporation

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KTB Tumorforschungs
  • Developer ImmunityBio; LadRx Corporation; NantKwest
  • Class Amines; Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Hexanoic acids; Hydrazines; Maleimides; Naphthacenes; Pyrroles; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Soft tissue sarcoma; Ovarian cancer; Pancreatic cancer; Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Soft tissue sarcoma
  • Phase II Glioblastoma; Kaposi's sarcoma; Pancreatic cancer; Small cell lung cancer
  • Phase I/II Chondrosarcoma; Colorectal cancer; Osteosarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer

Most Recent Events

  • 22 Jun 2023 XOMA in-licenses Aldoxorubicin from LadRx Corporation
  • 19 Jan 2023 Updated efficacy data from a phase II QUILT 88 trial in Pancreatic cancer released by ImmunityBio
  • 31 Dec 2022 ImmunityBio obtains aldoxorubicin-related patents from LadRx Corporation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top